Melanoma cell adhesion can be blocked by heparin in vitro: Suggestion of VLA-4 as a novel target for antimetastatic approaches

Thrombosis and Haemostasis

Volumn 100, Issue 6, 2008, Pages 1166-1175

  Fritzsche, Juliane ^a   Simonis, Dirk ^a   Bendas, Gerd ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cancer; Cell cell interactions; Heparins; Integrins; Melanoma

Indexed keywords

CD146 ANTIGEN; ENOXAPARIN; HEPARIN; HEPARIN NATRIUM 5000 RATIOPHARM; INTEGRIN; L SELECTIN; MONOCLONAL ANTIBODY; PADGEM PROTEIN; SELECTIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL ADHESION; CELL INTERACTION; CELL ISOLATION; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; METASTASIS; METASTASIS INHIBITION; MICROEMBOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; THROMBOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; CELL ADHESION; CELL LINE, TUMOR; ENDOTHELIAL CELLS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTEGRIN ALPHA4BETA1; L-SELECTIN; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; P-SELECTIN; STRESS, MECHANICAL; TIME FACTORS; U937 CELLS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 57349172005     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-05-0332     Document Type: Article

References (47)

1. Borsig L, Wong R, Feramisco J, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumour metastasis. Proc Natl Acad Sci USA 2001; 98: 3352-3357.
2. Ludwig RJ, Boehme B, Podda M, et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004; 64: 2743-2750.
3. Läubli H, Stevenson JL, Varki A, et al. L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumour cell arrest. Cancer Res 2006; 66: 1536-1542.
4. Nieswandt B, Hafner M, Echtenacher B, et al. Lysis of tumour cells by natural killer cells is in mice is impeded by platelets. Cancer Res 1999; 59: 1295-1300.
5. Borsig L, Wong R, Hynes RO, et al. Synergistic effects of L- and P-selectin in facilitating tumour metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA 2002; 99: 2193-2198.
6. Krause T, Turner GA. Are selectins involved in metastasis? Clinical & Experimental Metastasis 1999; 17: 183-192.
7. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60: 577-584.
8. Mattila P, Majuri ML, Renkonen R. VLA-4 integrin on sarcoma cell lines recognizes endothelial VCAM-1. Differential regulation of the VLA-4 avidity on various sarcoma cell lines. Int J Cancer 2006; 52: 918-923.
9. Klemke M, Weschenfelder T, Konstandin MH, et al. High affinity interaction of integrin a4b1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J Cell Physiol 2007; 212: 368-374.
10. Okahara H, Yagita H, Miyake K, et al. Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumour necrosis factor alpha enhancement of experimental metastasis. Cancer Res 1994; 54: 3233-3236.
11. Garofalo A, Chirivi RG, Foglieni C, et al. Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases. Cancer Res 1995; 55: 414-419.
12. Schadendorf D, Heidel J, Gawlik C, et al. Association With Clinical Outcome of Expression of VLA-4 in Primary Cutaneous Malignant Melanoma as Well as P-selectin and E-selectin on Intratumoral Vessels. J Natl Cancer Inst 1995; 87: 366-371.
13. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.
14. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266-1271.
15. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-2135.
16. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2129.
17. Niers TM, Klerk CP, DiNisio M, et al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007; 61: 195-207.
18. Yoshitomi Y, Nakanishi H, Kusano Y, et al. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett 2004; 207: 165-174.
19. Kragh M, Binderup L, Vig Hjarnaa PJ, et al. Non-anticoagulant heparin inhibits metastasis but not primary tumour growth. Oncol Rep 2005; 14: 99-104.
20. Hostettler N, Naggi A, Torri G, et al. P-selectin and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. Faseb J 2007; 21: 3562-3572.
21. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005; 11: 7003-7011.
22. Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004; 92: 627-633.
23. Jayson GC, Gallagher JT. Heparin oligosaccharides: inhibition of the biological activity of bFGF on Caco-2 cells. Br J Cancer 1997; 75: 9-16.
24. Vlodavsky I, Abboud-Jarrous G, Elkin M, et al. The impact of heparanase and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 2006; 35: 116-127.
25. Kim YJ, Borsig L, Varki NM, et al. P-selectin deficiency attenuates tumour growth and metastasis. Proc Natl Acad Sci USA 1998; 95: 9325-9330.
26. Fritzsche J, Alban S, Ludwig RJ, et al. The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity. Biochem Pharmacol 2006; 72: 474-485.
27. Simonis D, Fritzsche J, Alban S, et al. Kinetic analysis of heparin and glucan sulfates binding to P-selectin and its impact on the general understanding of selectin inhibition. Biochemistry 2007; 46: 6156-6164.
28. Robert C, Fuhlbrigge RG, Kieffer JD, et al. Interaction of dendritic cells with skin endothelium: a new perspective on immunosurveillance. J Exp Med 1999; 189: 627-636.
29. Ma YQ, Geng JG. Heparan sulfate-like proteoglycans mediate adhesion of human malignant melanoma A375 cells to P-selectin under flow. J Immunol 2000; 165: 558-565.
30. Hanley W, McCarty O, Jadhav S, et al. Single molecule characterization of P-selectin/ligand binding. J Biol Chem 2003; 278: 10556-10561.
31. Aigner S, Sthoeger ZM, Fogel M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumour cells. Blood 1997; 89: 3385-3395.
32. Garcia J, Callewaert N, Borsig L. P-selectin mediates metastatic progression through binding to sulfatides on tumour cells. Glycobiology 2007; 17: 185-196.
33. Dardik R, Savion N, Kaufmann Y, et al. Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: role of platelet glycoproteins P-selectin and GPIIb-IIIA. Br J Cancer 1998; 77: 2069-2075.
34. Sobel M, Fish WR, Toma N, et al. Heparin modulates integrin function in human platelets. J Vasc Surg 2001; 33: 587-594.
35. Kim YJ, Borsig L, Han HL, et al. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am J Pathol 1999; 155: 461-472.
36. Ohyama C, Tsuboi S, Fukuda M. Dual roles of sialyl Lewis X oligosaccharides in tumour metastasis and rejection by natural killer cells. EMBO J 1999; 18: 1516-1525.
37. Sikorski EE, Hallmann R, Berg EL, et al. The Peyer's patch high endothelial receptor for lymphocytes, the mucosal vascular addressin, is induced on a murine endothelial cell line by tumour necrosis factor-alpha and IL-1. J Immunol 1993; 151: 5239-5250.
38. Gosk S, Moos T, Gottstein C, et al. VCAM-1 directed immunoliposomes selectively target tumour vasculature in vivo. Biochim Biophys Acta 2008; 1778: 854-863.
39. Robledo MM, Bartolomé RA, Longo N, et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001; 276: 45098-45105.
40. Cardones AR, Murakami T, Hwang ST. CXCR4 enhances adhesion of B16 tumour cells to endothelial cells in vitro and in vivo via β1 integrin. Cancer Res 2003; 63: 6751-6757.
41. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007; 25: 619-647.
42. Vonderheide RH, Springer TA. Lymphocyte adhesion through very late activation antigen 4: Evidence for a novel binding site in the alternatively spliced domain of vascular cell adhesion molecule 1 and an additional α4 integrin counter-receptor on stimulated endothelium. J Exp Med 1992; 175: 1433-1442.
43. Saini A, Seller Z, Davies D, et al. Activation status and function of the VLA-4 (a4b1) integrin expressed on human melanoma cell lines. Int J Cancer 1997; 73: 264-270.
44. Nakayama J, Guan XC, Nakashima M, et al. In vitro comparison between mouse B16 and human melanoma cell lines of the expression of ICAM-1 induced by cytokines and/or hyperthermia. J Dermatol 1997; 24: 351-360.
45. Da Silva MS, Horton JA, Wijelath JM, et al. Heparin modulates integrin-mediated cellular adhesion: specificity of interactions with alpha and beta integrin subunits. Cell Commun Adhes 2003; 10: 59-67.
46. Diamond MS, Alon R, Parkos CA, et al. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD18). J Cell Biol 1995; 130: 1473-1482.
47. Vorup-Jensen T, Chi L, Gjelstrup LC, et al. Binding between the integrin αXβ2 (CD11c/CD18) and heparin. J Biol Chem 2007; 282: 30869-30877.